ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for monitor Customisable watchlists with full streaming quotes from leading exchanges, such as LSE, NASDAQ, NYSE, AMEX, Bovespa, BIT and more.

TWST Twist Bioscience Corporation

58.66
2.51 (4.47%)
After Hours
Last Updated: 23:31:45
Delayed by 15 minutes
Share Name Share Symbol Market Type
Twist Bioscience Corporation NASDAQ:TWST NASDAQ Common Stock
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  2.51 4.47% 58.66 58.66 59.43 59.43 56.61 56.92 1,282,124 23:31:45

TWST SHAREHOLDER ALERT: Jakubowitz Law Reminds Twist Shareholders of a Lead Plaintiff Deadline of February 10, 2023

16/12/2022 10:45am

PR Newswire (US)


Twist Bioscience (NASDAQ:TWST)
Historical Stock Chart


From Jul 2022 to Jul 2024

Click Here for more Twist Bioscience Charts.

NEW YORK, Dec. 16, 2022 /PRNewswire/ -- Jakubowitz Law announces that a securities fraud class action lawsuit has commenced on behalf of shareholders of Twist Bioscience Corporation (NASDAQ: TWST).

To receive updates on the lawsuit, fill out the form:
https://claimyourloss.com/securities/twist-bioscience-corporation-loss-submission-form/?id=34668&from=4

This lawsuit is on behalf of a class of all persons and entities who purchased or otherwise acquired Twist common stock between December 13, 2019 and November 14, 2022, inclusive.

Shareholders interested in acting as a lead plaintiff representing the class of wronged shareholders have until February 10, 2023 to petition the court. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.

According to a filed complaint, Twist Bioscience Corporation issued materially false and/or misleading statements and/or failed to disclose that: 1) as alleged in the November 15, 2022 report by Scorpion Capital, defendants overstated the commercial viability of Twist's synthetic DNA manufacturing technology; and 2) at the same time, defendants were engaging in accounting fraud and using unsustainable pricing to inflate the Company's true financial condition and prospects.

Jakubowitz Law is vigorous in pursuit of justice for shareholders who have been the victim of securities fraud. Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:
JAKUBOWITZ LAW
1140 Avenue of the Americas
9th Floor
New York, New York 10036
T: (212) 867-4490
F: (212) 537-5887

Cision View original content:https://www.prnewswire.com/news-releases/twst-shareholder-alert-jakubowitz-law-reminds-twist-shareholders-of-a-lead-plaintiff-deadline-of-february-10-2023-301704936.html

SOURCE Jakubowitz Law

Copyright 2022 PR Newswire

1 Year Twist Bioscience Chart

1 Year Twist Bioscience Chart

1 Month Twist Bioscience Chart

1 Month Twist Bioscience Chart